sábado, 9 de abril de 2016
Cancer Currents Blog: Drug Combination Shrinks Duodenal Polyps in People with Familial Adenomatous Polyposis
Drug Combo Shrinks Duodenal Polyps in FAP - National Cancer Institute
In a small clinical trial of people with an inherited condition that greatly increases the risk of developing gastrointestinal cancers, a two-drug combination has been shown to shrink duodenal polyps, precursor lesions for cancer, raising the possibility that the regimen could lower the risk of duodenal cancer. In the randomized trial, patients with the condition, familial adenomatous polyposis (FAP), who took erlotinib (Tarceva®) and sulindac (Aflodac®) had far fewer precancerous polyps in the duodenum—the first section of the small intestine, just beyond the stomach—than patients who took placebo. The benefit was so pronounced that the trial was stopped early, after only two-thirds of the planned number of participants had completed treatment.